Clinical Benefits of Dapagliflozin for T2D Remain Irrespective of Background Therapy
Dapagliflozin consistently reduced the risk of CV death or HHF, HHF alone, and progression of kidney disease regardless of background use of CV medications, investigators say.
Statin Use Associated with Largest Effect in First 6 Months After ASCVD Event
Nearly half of the study cohort did not fill a statin prescription within 90 days after an ASCVD event.
No Association Observed in Time From TAVI to Noncardiac Surgery, Adverse Outcomes
Timing, urgency, and risk category of surgery were not associated with increased risk of the primary end point.
12 Risk Factors Linked to Dementia Could Be Modified, Reduce US Cases by 400,000
Preventable factors including obesity, hypertension, and physical activity are disparately impacting the rate of dementia among people of color.
Continuous VTE Risk Observed After Lower Extremity Revascularization in Patients with PAD
New findings suggest low-dose rivaroxaban plus aspirin was associated with lower VTE risk compared with aspirin alone.
